Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/06/2925573/31990/en/Agios-to-Receive-1-1-Billion-in-Milestone-Payments-Following-FDA-Approval-of-Vorasidenib.html
https://www.fiercepharma.com/pharma/agios-looking-widen-pool-rare-blood-disorder-therapy-pyrukynd-misses-mark-first-pediatric
https://www.globenewswire.com/news-release/2024/08/01/2922584/31990/en/Agios-Reports-Business-Highlights-and-Second-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/08/01/2922579/31990/en/Agios-Announces-Results-from-Phase-3-ACTIVATE-KidsT-Study-of-Mitapivat-in-Children-with-PK-Deficiency-Who-Are-Regularly-Transfused.html
https://www.globenewswire.com/news-release/2024/07/18/2915139/31990/en/Agios-to-Webcast-Conference-Call-of-Second-Quarter-2024-Financial-Results-on-August-1-2024.html
https://www.globenewswire.com/news-release/2024/06/15/2899255/31990/en/Agios-Presents-Positive-Results-from-Phase-3-ENERGIZE-Study-of-Mitapivat-in-Non-Transfusion-Dependent-Thalassemia-in-Plenary-Session-at-the-European-Hematology-Association-2024-Hyb.html
https://www.globenewswire.com/news-release/2024/06/06/2894716/31990/en/Updated-Time-Agios-to-Present-at-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference-on-June-10-2024-at-8-40-am-ET.html
https://www.globenewswire.com/news-release/2024/06/03/2892080/31990/en/Agios-Announces-Phase-3-ENERGIZE-T-Study-of-Mitapivat-Met-Primary-Endpoint-and-All-Key-Secondary-Endpoints-in-Adults-with-Transfusion-Dependent-Alpha-or-Beta-Thalassemia.html
https://www.reuters.com/business/healthcare-pharmaceuticals/agios-pharmaceuticals-blood-disorder-drug-succeeds-late-stage-study-2024-06-03/
https://www.globenewswire.com/news-release/2024/05/30/2891120/31990/en/Agios-to-Present-at-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference-on-June-10-2024.html